Gyre Therapeutics, Inc. Deferred Income Tax Assets, Net
Gyre Therapeutics, Inc. (GYRE) had Deferred Income Tax Assets, Net of $9.28 million as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:DeferredIncomeTaxAssetsNet · last filed 2026-08-07
- 2026-06-30: Deferred Income Tax Assets, Net $9.28M.
- 2026-03-31: Deferred Income Tax Assets, Net $7.72M.
- 2025-12-31: Deferred Income Tax Assets, Net $6.87M.
- 2025-09-30: Deferred Income Tax Assets, Net $6.71M.
| Period end | Deferred Income Tax Assets, Net |
|---|---|
| 2026-06-30 | $9.28M 10-Q · filed 2026-08-07 |
| 2026-03-31 | $7.72M 10-Q · filed 2026-05-08 |
| 2025-12-31 | $6.87M 10-Q · filed 2026-08-07 |
| 2025-09-30 | $6.71M 10-Q · filed 2025-11-07 |
| 2025-06-30 | $6.13M 10-Q · filed 2025-08-11 |
| 2025-03-31 | $5.82M 10-Q · filed 2025-05-09 |
| 2024-12-31 | $5.62M 10-K · filed 2026-03-13 |
| 2024-09-30 | $5.16M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $5.08M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $5.00M 10-Q · filed 2024-05-13 |
| 2023-12-31 | $4.70M 10-K · filed 2025-03-17 |
| 2022-12-31 | $4.08M 10-K · filed 2024-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |